ProgramDirector/PrincipalInvestigator(Last,Rrst,Middle):Leof,Edward,B PROJECT SUMMARY (See Instmctions): A central paradox in transforming growth factor beta (TGF-p) biology is how the same growth ^ctor can induce such divergent responses as growth stimulation (i.e., mesenchymal cells) and growth inhibition (i.e., epithelial cells)? Considering the pivotal role TGF-^ has in a number of nomial and pathological conditions, addressing that issue is fundamental if we hope to develop specific intervention strategies. To that end, we have been investigating the general hypothesis that the cellular response to TGF-? is dependent upon an integrated action ofthe trafficldng and signaling machinery. In support of that proposal, we have detemiined that (i) in polarized epithelial cells TGF-p receptors traffic to the basolateral domain, adjacent to the junctional complex;(ii) the mammalian retromer complex specifically maintains type II TGF-p receptor polarity by controlling recycling endosome to plasma membrane delivery by way of clathrin, EEA1 and Rab11 positive compartments;(iii) sorting nexin 9 (SNX9), a known trafficking protein, has a new role in TGF-p signaling downstream of its canonical plasma membriane action;(iv) an unique mechanism has been defined by which specificity in TGF-p signaling can be controlled and subsequently exploited to treat diseases dependent upon Smad3;(v) profibrotic TGF-p responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases;and, most importantly, (vi) utilizing a treatment model of lung fibrosis, provided preclinical data documenting that physiologic parameters of lung function can be stabilized by targeting multiple TGF-p regulated pathways. We propose to extend these findings using a variety of biochemical, biological, and genetic approaches. First, the receptor elements and cellular factors controlling TGF-p receptor trafficking as well as the role of retromer in TGF-p stimulated EMT/migration will be defined. As a number of diseases result from defects in the ability to sort or transport proteins to defined cellular locales, characterizing the operative trans-acting factors provides potential mechanisms to alter the cellular response to TGF-p. Second, the role of SNX9 in regulating Smad3-dependent phenotypes including lung fibrosis and glioblastoma progression will be determined. In that upwards of 45% of all deaths in the developed wortd are attributed to some sort of chronic fibroproliferative disorder, and the median progression-free and sun/ival for glioblastoma with current chemoradiation is ~7 and 15 months, respectively, new approaches are clearly needed.
TGF-p is a protein that can be either helpful or harmful to human health. While its ability to stimulate cell growth is important for normal wound healing, when unchecked the function of many organs can be disrupted by scar (i.e., fibrosis) formation. Conversely, the growth inhibitory actions of TGF-p are critical in preventing cancer. The proposed studies will identify/characterize targets that can be used to either increase or decrease these re.sDnnses.
|Yin, Xueqian; Murphy, Stephen J; Wilkes, Mark C et al. (2013) Retromer maintains basolateral distribution of the type II TGF-* receptor via the recycling endosome. Mol Biol Cell 24:2285-98|
|Andrianifahanana, Mahefatiana; Wilkes, Mark C; Gupta, Shiv K et al. (2013) Profibrotic TGF* responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. FASEB J 27:4444-54|
|Hong, Min; Wilkes, Mark C; Penheiter, Sumedha G et al. (2011) Non-Smad transforming growth factor-ýý signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 286:17841-50|
|Penheiter, Sumedha G; Singh, Raman Deep; Repellin, Claire E et al. (2010) Type II transforming growth factor-beta receptor recycling is dependent upon the clathrin adaptor protein Dab2. Mol Biol Cell 21:4009-19|
|Wang, Shinong; Wilkes, Mark C; Leof, Edward B et al. (2010) Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298:F142-9|
|Andrianifahanana, Mahefatiana; Wilkes, Mark C; Repellin, Claire E et al. (2010) ERBB receptor activation is required for profibrotic responses to transforming growth factor beta. Cancer Res 70:7421-30|
|Wilkes, Mark C; Repellin, Claire E; Hong, Min et al. (2009) Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. Dev Cell 16:433-44|
|Murphy, Stephen J; Shapira, Keren E; Henis, Yoav I et al. (2007) A unique element in the cytoplasmic tail of the type II transforming growth factor-beta receptor controls basolateral delivery. Mol Biol Cell 18:3788-99|
|Rahimi, Rod A; Leof, Edward B (2007) TGF-beta signaling: a tale of two responses. J Cell Biochem 102:593-608|